Professional Education

  • Doctor of Philosophy, Universite De Paris Vii (2018)
  • Master of Science, University Of Pune (2014)

Current Research and Scholarly Interests

Human cancers develop due to accumulation of somatic mutations which result from diverse processes including exposure to environmental mutagens such as UV light, tobacco smoke as well as endogenous DNA damaging processes like replication errors, spontaneous or enzymatic conversions. I develop computational methods in order to investigate these various patterns of mutational signatures that arise in cancer genomes. The major focus of my research is based on understanding the interaction of intracellular processes with diverse mutational processes and ultimately their contribution towards cancer evolution. Studying these complex patterns of mutational heterogeneity might be useful in effective patient stratification. My career goals are to use cancer metadata and omics data, with computational modeling, and big data analytics in order to improve cancer care.

All Publications

  • Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress NATURE COMMUNICATIONS Bayard, Q., Meunier, L., Peneau, C., Renault, V., Shinde, J., Nault, J., Mami, I., Couchy, G., Amaddeo, G., Tubacher, E., Bacq, D., Meyer, V., La Bella, T., Debaillon-Vesque, A., Bioulac-Sage, P., Seror, O., Blanc, J., Calderaro, J., Deleuze, J., Imbeaud, S., Zucman-Rossi, J., Letouze, E. 2018; 9: 5235


    Cyclins A2 and E1 regulate the cell cycle by promoting S phase entry and progression. Here, we identify a hepatocellular carcinoma (HCC) subgroup exhibiting cyclin activation through various mechanisms including hepatitis B virus (HBV) and adeno-associated virus type 2 (AAV2) insertions, enhancer hijacking and recurrent CCNA2 fusions. Cyclin A2 or E1 alterations define a homogenous entity of aggressive HCC, mostly developed in non-cirrhotic patients, characterized by a transcriptional activation of E2F and ATR pathways and a high frequency of RB1 and PTEN inactivation. Cyclin-driven HCC display a unique signature of structural rearrangements with hundreds of tandem duplications and templated insertions frequently activating TERT promoter. These rearrangements, strongly enriched in early-replicated active chromatin regions, are consistent with a break-induced replication mechanism. Pan-cancer analysis reveals a similar signature in BRCA1-mutated breast and ovarian cancers. Together, this analysis reveals a new poor prognosis HCC entity and a rearrangement signature related to replication stress.

    View details for DOI 10.1038/s41467-018-07552-9

    View details for Web of Science ID 000452633000003

    View details for PubMedID 30531861

    View details for PubMedCentralID PMC6286353

  • Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer BIOINFORMATICS Shinde, J., Bayard, Q., Imbeaud, S., Hirsch, T. Z., Liu, F., Renault, V., Zucman-Rossi, J., Letouze, E. 2018; 34 (19): 3380–81


    Cancer genomes are altered by various mutational processes and, like palimpsests, bear the signatures of these different processes. The Palimpsest R package provides a complete workflow for the characterization and visualization of mutational signatures and their evolution along tumor development. The package covers a wide range of functions for extracting both base substitution and structural variant signatures, inferring the clonality of each alteration and analyzing the evolution of mutational processes between early clonal and late subclonal events. Palimpsest also estimates the probability of each mutation being due to each process to predict the mechanisms at the origin of driver events. Palimpsest is an easy-to-use toolset for reconstructing the natural history of a tumor using whole exome or whole genome sequencing data.Palimpsest is freely available at data are available at Bioinformatics online.

    View details for DOI 10.1093/bioinformatics/bty388

    View details for Web of Science ID 000446434300018

    View details for PubMedID 29771315

  • Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis NATURE COMMUNICATIONS Letouze, E., Shinde, J., Renault, V., Couchy, G., Blanc, J., Tubacher, E., Bayard, Q., Bacq, D., Meyer, V., Semhoun, J., Bioulac-Sage, P., Prevot, S., Azoulay, D., Paradis, V., Imbeaud, S., Deleuze, J., Zucman-Rossi, J. 2017; 8: 1315


    Genomic alterations driving tumorigenesis result from the interaction of environmental exposures and endogenous cellular processes. With a diversity of risk factors, liver cancer is an ideal model to study these interactions. Here, we analyze the whole genomes of 44 new and 264 published liver cancers and we identify 10 mutational and 6 structural rearrangement signatures showing distinct relationships with environmental exposures, replication, transcription, and driver genes. The liver cancer-specific signature 16, associated with alcohol, displays a unique feature of transcription-coupled damage and is the main source of CTNNB1 mutations. Flood of insertions/deletions (indels) are identified in very highly expressed hepato-specific genes, likely resulting from replication-transcription collisions. Reconstruction of sub-clonal architecture reveals mutational signature evolution during tumor development exemplified by the vanishing of aflatoxin B1 signature in African migrants. Finally, chromosome duplications occur late and may represent rate-limiting events in tumorigenesis. These findings shed new light on the natural history of liver cancers.

    View details for DOI 10.1038/s41467-017-01358-x

    View details for Web of Science ID 000414376900016

    View details for PubMedID 29101368

    View details for PubMedCentralID PMC5670220

  • Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas JOURNAL OF PATHOLOGY Pilati, C., Shinde, J., Alexandrov, L. B., Assie, G., Andre, T., Helias-Rodzewicz, Z., Ducoudray, R., Le Corre, D., Zucman-Rossi, J., Emile, J., Bertherat, J., Letouze, E., Laurent-Puig, P. 2017; 242 (1): 10–15


    Germline alterations in DNA repair genes are implicated in cancer predisposition and can result in characteristic mutational signatures. However, specific mutational signatures associated with base excision repair (BER) defects remain to be characterized. Here, by analysing a series of colorectal cancers (CRCs) using exome sequencing, we identified a particular spectrum of somatic mutations characterized by an enrichment of C > A transversions in NpCpA or NpCpT contexts in three tumours from a MUTYH-associated polyposis (MAP) patient and in two cases harbouring pathogenic germline MUTYH mutations. In two series of adrenocortical carcinomas (ACCs), we identified four tumours with a similar signature also presenting germline MUTYH mutations. Taken together, these findings demonstrate that MUTYH inactivation results in a particular mutational signature, which may serve as a useful marker of BER-related genomic instability in new cancer types. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

    View details for DOI 10.1002/path.4880

    View details for Web of Science ID 000399674800003

    View details for PubMedID 28127763

  • Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets NATURE GENETICS Schulze, K., Imbeaud, S., Letouze, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., Calatayud, A., Pinyol, R., Pelletier, L., Balabaud, C., Laurent, A., Blanc, J., Mazzaferro, V., Calvo, F., Villanueva, A., Nault, J., Bioulac-Sage, P., Stratton, M. R., Llovet, J. M., Zucman-Rossi, J. 2015; 47 (5): 505–U106


    Genomic analyses promise to improve tumor characterization to optimize personalized treatment for patients with hepatocellular carcinoma (HCC). Exome sequencing analysis of 243 liver tumors identified mutational signatures associated with specific risk factors, mainly combined alcohol and tobacco consumption and exposure to aflatoxin B1. We identified 161 putative driver genes associated with 11 recurrently altered pathways. Associations of mutations defined 3 groups of genes related to risk factors and centered on CTNNB1 (alcohol), TP53 (hepatitis B virus, HBV) and AXIN1. Analyses according to tumor stage progression identified TERT promoter mutation as an early event, whereas FGF3, FGF4, FGF19 or CCND1 amplification and TP53 and CDKN2A alterations appeared at more advanced stages in aggressive tumors. In 28% of the tumors, we identified genetic alterations potentially targetable by US Food and Drug Administration (FDA)-approved drugs. In conclusion, we identified risk factor-specific mutational signatures and defined the extensive landscape of altered genes and pathways in HCC, which will be useful to design clinical trials for targeted therapy.

    View details for DOI 10.1038/ng.3252

    View details for Web of Science ID 000353635800013

    View details for PubMedID 25822088

    View details for PubMedCentralID PMC4587544